Corona Remedies544644Quarterly results
Board approves unaudited Q2 and H1 results; auditors' review conclusion not modified
Board met on 30 October 2026 (03:30 p.m. to 04:40 p.m.) and approved the unaudited standalone and consolidated financial results for the quarter and half year ended 30 September 2026, along with the limited review reports.
By ScoutQuest · · 2 min read
| Line item | Latest | Year ago | YoY | Prev qtr | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 441.17 | 361.13 | +22.2% | 422.43 | +4.4% |
| Total income | 443.65 | 363.40 | +22.1% | 425.58 | +4.2% |
| Profit before tax | 80.75 | 69.78 | +15.7% | 80.36 | +0.5% |
| Profit after tax | 60.31 | 52.32 | +15.3% | 60.11 | +0.3% |
| Total comprehensive income | 59.60 | 52.63 | +13.2% | 59.81 | −0.4% |
| Basic EPS | 9.86 | 8.55 | +15.3% | 9.83 | +0.3% |
- Total income
- Latest 443.65; Year ago 363.40 (+22.1%); Prev qtr 425.58 (+4.2%)
- Profit after tax
- Latest 60.31; Year ago 52.32 (+15.3%); Prev qtr 60.11 (+0.3%)
- Period
- 30 September 2026 (Unaudited)
Auditor's review
Conclusion: Unmodified
Notes to the results
- Exceptional item: Statutory impact of new Labour Codes of Rs.19.10 crores (post tax Rs.14.29 crores) recognised in the year ended 31 March 2026 (gratuity Rs.13.60 crores, compensated absences Rs.5.50 crores).
Board meeting and what was approved
- The board met on 30 October 2026 from 03:30 p.m. to 04:40 p.m. and approved the unaudited standalone and consolidated financial results for the quarter and half year ended 30 September 2026, along with the limited review reports.
- The Audit Committee reviewed the results before the board approved them.
- The results will be advertised and are placed on the company's website; a press release on the results is being shared with the media.
- The company reports only one business segment, Pharmaceuticals.
Auditor's review conclusion
- Walker Chandiok & Co LLP reviewed the standalone and consolidated results. A review is narrower than a full audit, so the auditors do not express an audit opinion.
- Their conclusion: nothing came to their attention that causes them to believe the statements contain a material misstatement or fail the required disclosures. The conclusion is not modified.
- The consolidated statement includes one associate, La Chandra Pharma Lab Private Limited, whose figures were reviewed by another auditor and the conclusion relies on that report.
Standalone results (Rs. in crore)
- Quarter ended 30 September 2026: Revenue from operations 441.17, Total income 443.65, Net Profit after tax 60.18.
- Half year ended 30 September 2026: Revenue from operations 863.60, Net profit after tax 120.28.
Other notes in the update
- Labour Codes: an exceptional item of Rs. 19.10 crores was presented as the statutory impact of the new Labour Codes, shown in the year ended 31 March 2026.
- Overdraft facilities of Rs. 94.28 Crores were availed and disclosed under short-term borrowings.
- The equity shares were listed on NSE and BSE on 15 December 2025 after an initial public offering that was an offer for sale of 61,74,051 equity shares by selling shareholders; the total IPO expenses (except listing fees) were borne by the selling shareholders.
How to read this
- The update gives the latest audited-by-review revenue and profit lines for the quarter and half year, plus the auditor's conclusion that it found no material issue in the statements.
- The note on Labour Codes and the overdraft disclosure explain two non-operating items that sit around the reported numbers.
₹120.28 CrNet profit after tax, standalone
Profit after tax, latest quarter60.31 (Rs. in Crores)
Profit after tax, quarter60.11 (Rs. in Crores)
Also from Corona Remedies
Corona Remedies Q2 FY27 revenue up 22.2% to INR 441.2 Cr; H1 PAT up 22.2% to INR 120.4 Cr
30 Oct 2026
Corona Remedies Ltd press release, Q2 FY27
30 Oct 2026
Corona Remedies Ltd press release
22 Oct 2026
More numbers
- Net Profit after tax, standalone, quarter ended 30 Sep 202660.18
- Revenue from operations, standalone, half year ended 30 Sep 2026863.60
- Net profit after tax, standalone, half year ended 30 Sep 2026120.28
- Statutory impact of new Labour Codes (exceptional item)Rs.19.10 crores
- Overdraft facilities availedRs. 94.28 Crores
- Equity shares offered for sale in IPO61,74,051
- Total income, latest quarter443.65 (Rs. in Crores)
- Total income, year-ago quarter363.40 (Rs. in Crores)
- Total income, previous quarter425.58 (Rs. in Crores)
- Total comprehensive income, latest quarter59.60 (Rs. in Crores)
- Total comprehensive income, year-ago quarter52.63 (Rs. in Crores)
- Total comprehensive income, previous quarter59.81 (Rs. in Crores)
- Profit after tax, latest quarter60.31 (Rs. in Crores)
- Profit after tax, year-ago quarter52.32 (Rs. in Crores)
- Profit after tax, previous quarter60.11 (Rs. in Crores)
- Revenue from operations, latest quarter441.17 (Rs. in Crores)
- Revenue from operations, year-ago quarter361.13 (Rs. in Crores)
- Revenue from operations, previous quarter422.43 (Rs. in Crores)
- Profit before tax, latest quarter80.75 (Rs. in Crores)
- Profit before tax, year-ago quarter69.78 (Rs. in Crores)
- Profit before tax, previous quarter80.36 (Rs. in Crores)
Source: BSE · 30 Oct 2026
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.